Jonathan Brammer, MD
Hematology · Columbus, OHNPI 1578897195
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $31,970 of the $37,951 with a category attached, or 84.2%. Seagen Inc. accounts for 86.6% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2020 at $12,928 and has fallen 73.7% since, to $3,402 in 2025.
Across 36 payments — averaging $1054.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$33K
- Pfizer$3K
- Verastem, Inc.$2K
- Daiichi Sankyo Inc.$184
Across 104 payments — averaging $7794.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Daiichi Sankyo Inc.$220K
- Secura Bio, Inc.$215K
- Bristol Myers Squibb$160K
- Incyte Corporation$109K
- Verastem, Inc.$105K
- Aptevo Therapeutics Inc$3K
What the payments were for
- Speaking & faculty fees$31,97084%
- Travel & lodging$4,65612%
- Food & beverage$1,3253%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 26 | $32,864 |
| Pfizer | 3 | $3,402 |
| Verastem, Inc. | 5 | $1,502 |
| Daiichi Sankyo Inc. | 2 | $184 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$37,951 in reported general payments places this provider in the 75th percentile of 84 hematology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 83 | $1,459,146 |
| ValacyclovirValacyclovir Hcl | 14 | $389 |
Paid to pharmacies, not to this prescriber.
Other hematology in Columbus
- Uma BorateColumbus$323K
- Sam PenzaColumbus$256K
- Spero CatalandColumbus$245K
- Kami MaddocksColumbus$236K
- Narendranath EpperlaColumbus$199K
- Yvonne EfeberaColumbus$169K
- Naresh BummaColumbus$109K
- Kerry RogersColumbus$100K
- Jennifer WoyachColumbus$73K
- Hannah ChoeColumbus$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.